China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under this collaboration, HitGen will leverage its DNA-encoded library (DEL) technology platform, which specializes in the design, synthesis, and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also provide support for ARase programs from hit-to-lead chemistry to pre-clinical development. Financial details of the agreement were not disclosed.
ARase’s Focus on ADP-Ribose Hydrolases and HitGen’s DEL Expertise
ARase is a biotechnology company focused on developing first-in-class therapeutics that target ADP-ribose hydrolases, enzymes that play a crucial role in various biological processes. HitGen, a global leader in the development of DEL technology and its applications to early-stage small molecule drug discovery, offers a platform that includes over 1.2 trillion small molecules generated by DEL technology. The efficiency of HitGen’s screening process has enabled the company to facilitate drug discovery projects for numerous organizations globally.
Combining Expertise for Oncology Drug Discovery
This partnership combines ARase’s focus on innovative therapeutics with HitGen’s expertise in DEL technology, aiming to accelerate the discovery and development of novel inhibitors for oncology targets. The collaboration is expected to yield significant advancements in the field of oncology drug discovery, benefiting both companies and potentially transforming patient outcomes.-Fineline Info & Tech
